Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL. Edwards BJ, et al. Among authors: migliorati c. Lancet Oncol. 2008 Dec;9(12):1166-72. doi: 10.1016/S1470-2045(08)70305-X. Lancet Oncol. 2008. PMID: 19038763 Review.
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Diel IJ, et al. Among authors: migliorati c. Crit Rev Oncol Hematol. 2007 Dec;64(3):198-207. doi: 10.1016/j.critrevonc.2007.07.005. Epub 2007 Sep 12. Crit Rev Oncol Hematol. 2007. PMID: 17855108 Review.
Osteoporosis and its implications for dental patients.
Edwards BJ, Migliorati CA. Edwards BJ, et al. J Am Dent Assoc. 2008 May;139(5):545-52; quiz 625-6. doi: 10.14219/jada.archive.2008.0214. J Am Dent Assoc. 2008. PMID: 18451370 Review.
Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs.
Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA; American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Edwards BJ, et al. J Am Dent Assoc. 2008 Dec;139(12):1674-7. doi: 10.14219/jada.archive.2008.0110. J Am Dent Assoc. 2008. PMID: 19047674
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA. Nicolatou-Galitis O, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug;112(2):195-202. doi: 10.1016/j.tripleo.2011.02.037. Epub 2011 May 31. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011. PMID: 21622014
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.
Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H; American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Hellstein JW, et al. J Am Dent Assoc. 2011 Nov;142(11):1243-51. doi: 10.14219/jada.archive.2011.0108. J Am Dent Assoc. 2011. PMID: 22041409 Review.
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP. Yarom N, et al. J Clin Oncol. 2019 Sep 1;37(25):2270-2290. doi: 10.1200/JCO.19.01186. Epub 2019 Jul 22. J Clin Oncol. 2019. PMID: 31329513
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).
Bennett CL, Hoque S, Olivieri N, Taylor MA, Aboulafia D, Lubaczewski C, Bennett AC, Vemula J, Schooley B, Witherspoon BJ, Godwin AC, Ray PS, Yarnold PR, Ausdenmoore HC, Fishman M, Herring G, Ventrone A, Aldaco J, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Marx R, Migliorati C, Ruggiero S, Nabhan C, Carson KR, McKoy JM, Yang YT, Schoen MW, Knopf K, Martin L, Sartor O, Rosen S, Smith WK. Bennett CL, et al. Among authors: migliorati c. EClinicalMedicine. 2020 Dec 23;31:100693. doi: 10.1016/j.eclinm.2020.100693. eCollection 2021 Jan. EClinicalMedicine. 2020. PMID: 33554084 Free PMC article.
145 results